ulcerative colitis
Conditions
Interventions
granulocyte and monocyte apheresis (GMA), twice per week, 5 weeks continuously, total 10 times.
Sponsors
Kyoto Prefectural University of Medicine, Department of Molecular Gastroenterology and Hepatology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Over 4 points of Lichtiger index score and endoscopic Mayo score 2 and 3. A kind of the previous treatment and the concomitant drug do not matter The patient who judged that GMA treatment was appropriate along guidelines on Ministry of Health, Labour and Welfare
Exclusion criteria
Exclusion criteria: a) The re-registration patients for this study b) The number of granulocyte is under 2,000/mm3 c) A patient complicated with a serious infectious disease d) Patient with a serious heart trouble e) Patient with a serious renal trouble f) Patient with low blood pressure (maximum pressure is under 80mmHg) g) Patient with pregnancy h) Strength sthenia pro-extreme dehydration, solidification, patient of serious anemia (less than 8.0 g/dL of hemoglobin) i) Patient with malignant tumor j) Patient with stoma k) Patient who had surgery for intestine with 12 weeks l) Patient with serious complications out of intestinal tract m) Patient who had GMA treatment within 4 weeks n) Patient who had started or increased thiopurine within 8 weeks o) The patient who judged an arrangement to the final examination if the medical attendant was inappropriate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The relationship between the change of enterobacterial flora and improvement of endoscopic finding, clinical symptoms. | — |
Secondary
| Measure | Time frame |
|---|---|
| The change of inflammatory related gene expression in colonic mucosa after GMA treatment. | — |
Countries
Japan
Contacts
Public ContactKazuhiko Uchiyama
Kyoto Prefectural University of Medicine Department of Molecular Gastroenterology and Hepatology
Outcome results
None listed